Drugmaker Pfizer has announced a new leadership and organizational plan that will become effective upon completion of its acquisition of Wyeth.
Having our organizational structure in place is critical to the combined company being operational on day one, said Pfizer Chairman and CEO Jeff Kindler, who will continue to lead the company following the merger.
The plan, according to a news release, includes organizing the combined companies into nine global business units and establishing two distinct research divisions. Pfizer will also retain eight of Wyeths senior executives.
Under the plan, the companys global business units will be primary care, which will handle cardiovascular and central nervous system disease products; specialty care and vaccines; emerging markets, which will focus on underpenetrated markets such as the Middle East and China; oncology; established products; animal health; consumer health; nutritional health; and Capsugel, which manufactures capsule products.
The research divisions will be separated into the pharmatherapeutics research group, which will focus on small-molecule research, and the biotherapeutics research group, which will focus on large-molecule research, including vaccines. Each group will be made up of small scientific teams that will focus on specific therapeutic areas and will collaborate with academic, public- and private-sector institutions to further research.